EP1252172A2 - Compose comprenant un groupe fonctionnel peptidique et un groupe fonctionnel silane organique - Google Patents
Compose comprenant un groupe fonctionnel peptidique et un groupe fonctionnel silane organiqueInfo
- Publication number
- EP1252172A2 EP1252172A2 EP00993511A EP00993511A EP1252172A2 EP 1252172 A2 EP1252172 A2 EP 1252172A2 EP 00993511 A EP00993511 A EP 00993511A EP 00993511 A EP00993511 A EP 00993511A EP 1252172 A2 EP1252172 A2 EP 1252172A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- moiety
- biomolecule
- reacted
- organo
- silane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 90
- 150000001282 organosilanes Chemical group 0.000 title claims abstract description 52
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 12
- 238000000034 method Methods 0.000 claims abstract description 50
- 230000008569 process Effects 0.000 claims abstract description 38
- 238000006243 chemical reaction Methods 0.000 claims abstract description 37
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 10
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 8
- 238000001668 nucleic acid synthesis Methods 0.000 claims abstract description 8
- 239000007795 chemical reaction product Substances 0.000 claims description 30
- 239000011521 glass Substances 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 125000005647 linker group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 230000001588 bifunctional effect Effects 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 230000002255 enzymatic effect Effects 0.000 claims description 7
- 238000006911 enzymatic reaction Methods 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- -1 N-(γ- maleimidobutyryloxy)succinimide ester Chemical class 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- 108700028369 Alleles Proteins 0.000 claims description 3
- 239000011324 bead Substances 0.000 claims description 3
- 238000007479 molecular analysis Methods 0.000 claims description 3
- 239000005057 Hexamethylene diisocyanate Substances 0.000 claims description 2
- 239000000020 Nitrocellulose Substances 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- RVJHDCPHSAUCEV-UHFFFAOYSA-N [2-(carbamothioylamino)phenyl]thiourea Chemical group NC(=S)NC1=CC=CC=C1NC(N)=S RVJHDCPHSAUCEV-UHFFFAOYSA-N 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000000732 arylene group Chemical group 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 238000010839 reverse transcription Methods 0.000 claims description 2
- 239000001226 triphosphate Substances 0.000 claims description 2
- 235000011178 triphosphate Nutrition 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims 2
- RPFLVLIPBDQGAQ-UHFFFAOYSA-N 1,2-diisothiocyanatobenzene Chemical compound S=C=NC1=CC=CC=C1N=C=S RPFLVLIPBDQGAQ-UHFFFAOYSA-N 0.000 claims 1
- 239000005289 controlled pore glass Substances 0.000 claims 1
- 238000004925 denaturation Methods 0.000 claims 1
- 230000036425 denaturation Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 21
- 102000053602 DNA Human genes 0.000 description 21
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 229940098773 bovine serum albumin Drugs 0.000 description 13
- 239000007790 solid phase Substances 0.000 description 13
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 12
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 108010006785 Taq Polymerase Proteins 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
- 230000027455 binding Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 229920002477 rna polymer Polymers 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 150000004756 silanes Chemical class 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical class NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 2
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 101710116602 DNA-Binding protein G5P Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010058683 Immobilized Proteins Proteins 0.000 description 2
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 2
- 101710162453 Replication factor A Proteins 0.000 description 2
- 101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 2
- 101710176276 SSB protein Proteins 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical group C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 229910000077 silane Inorganic materials 0.000 description 2
- 238000003746 solid phase reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 101000587453 Escherichia coli Plasmid-derived single-stranded DNA-binding protein Proteins 0.000 description 1
- 101000587458 Escherichia coli Plasmid-derived single-stranded DNA-binding protein Proteins 0.000 description 1
- 101000700922 Escherichia coli Plasmid-derived single-stranded DNA-binding protein Proteins 0.000 description 1
- 101000826084 Escherichia coli Plasmid-derived single-stranded DNA-binding protein Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 150000007930 O-acyl isoureas Chemical class 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- DLLXAZJTLIUPAI-XLPZGREQSA-N [[(2r,3s,5r)-5-(2-amino-4-oxo-1h-pyrrolo[2,3-d]pyrimidin-7-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2C=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 DLLXAZJTLIUPAI-XLPZGREQSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OMWQUXGVXQELIX-UHFFFAOYSA-N bitoscanate Chemical group S=C=NC1=CC=C(N=C=S)C=C1 OMWQUXGVXQELIX-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- UFJPAQSLHAGEBL-RRKCRQDMSA-N dITP Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(N=CNC2=O)=C2N=C1 UFJPAQSLHAGEBL-RRKCRQDMSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000012026 peptide coupling reagents Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 239000005451 thionucleotide Substances 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
Definitions
- nucleic acid sequence often involves analysis of the nucleic acid sequence, structure or composition of a given organism or sample. Frequently, such analysis incorporates the step of, or requires nucleic acid amplification.
- One of the well known methods for nucleic acid amplification is the "PCR", or polymerase chain reaction method also disclosed in US 4,683,195 and US 4,683,202.
- PCR polymerase chain reaction method also disclosed in US 4,683,195 and US 4,683,202.
- a nucleic acid sample serves as a template for a polymerase dependant in-vitro replication starting from two separate primers.
- Polymerases are enzymes capable of synthesising RNA or DNA making use of RNA or DNA as a template.
- RNA ribonucleic acid
- amplification additionally requires an enzymatic reverse transcription into DNA (deoxyribonucleic acid), but equally often on DNA.
- PCR is becoming powerful tool in diagnostics. PCR kits are becoming available for the detection and analysis of various pathogenic organisms as well e.g. mutant alleles of human genes.
- PCR is mostly performed in-vitro, i.e. in a tube whereby the components are mostly supplied in liquid format.
- the components usually being, a polymerase.
- a buffer, a template, two or more oligonucleotides. may be bound to some form of a solid-phase.
- EP0787205 discloses the use of linker between an oligonucleotide and the solid-support.
- the primers on a solid-support are not freely available in the reaction.
- the objects of the present invention are accomplished by providing for a compound with novel characteristics which may be used in solid phase enzymatic reactions, a processes for making this compound, as well as kits containing a compound according to the invention for use in processes according to the invention as well as other processes.
- the object of the present invention was accomplished by providing for a compound comprising a biomolecule moiety and an organo-silane moiety as represented in formula 1
- Rj, R 2 , and R are identical or different alkoxy groups, wherein alkoxy refers to groups of the general formula -OR.
- R is an alkyl rest
- BM represents a biomolecule moiety selected from the group comprising one or more amino acids, peptides and proteins and derivatives thereof and wherein, n is an integer from 0 to 18.
- the alkoxy groups Ri, R , and R 3 may, e.g. by methoxy. ethoxy or the like. Within the scope of the invention are organo-silane moieties comprising mixtures of different alkoxy groups.
- Ri may be a methoxy
- R 2 an ethoxy
- R 3 a methoxy
- the alkoxy groups Ri, R . and R 3 may equally well be identical. The skilled artisan is credited with the ability to discern alternative combinations which shall be within the scope of the invention.
- solid phase reactions and solid-support reactions are used with equal meaning and shall be understood as such reactions in which one or more compounds is attached to a solid matter of any given shape or chemical structure.
- a biomolecule is to be understood as any molecule which shows enzymatic activity, which acts as a probe in molecular analysis or which is the target of an enzymatic activity.
- one or more amino acids, peptides as well as proteins may be represented by the term bio- molecules "BM" within the scope of the invention.
- the compound according to the invention comprises an organo-silane as well as a biomolecule. It is obvious to one skilled in the art, that these two moieties may but must not be connected through one or more methylene groups.
- the compound according to the invention may thus also comprise the organo-silane group which is directly coupled to the methylene group.
- the organo- silane group is bound to between 1 and 18 methylene groups which are bound to the biomolecule.
- the inventors have found that synthesis of the compound according to the invention is facilitated if the compound according to the invention further comprises a linking moiety * interpost between the organo-silane moiety and the biomolecule moiety as represented by formula 2 formula 2:
- Ri, R 2 , and R are identical or different alkoxy groups and BM represents the biomolecule moiety or a derivative thereof, n is an integer from 0 to 18 and wherein, R_ t represents the linking moiety.
- the compound according to the invention is preferentially synthesised with the aid of homo- or hetero-bifunctional groups. These groups are used to specifically connect a methyl group or alternatively the organo-silane with the biomolecule. These groups result in the linking moiety R after reacting. Thus, such a linking moiety within the scope of the invention is to be understood as any moiety stemming from a homo- or hetero-bifunctional group after having reacted with an organo-silane and a biomolecule.
- organo-silane reacts both with other compounds according to the invention well, which may be desirable as outlined below as well as with various solid supports well if Ri, R 2 , and R 3 are each methoxy groups.
- Ri, R 2 , and R 3 are each methoxy groups.
- the biomolecule is preferentially coupled via a bifunctional linking moiety R to the organo- silane. It has been found that there are particularly suited bifunctional linking reagents for accomplishing this.
- bifunctional linking reagents may be selected from the group comprising arylenediisothiocyanate, alkylenediisothiocyanate, bis-N-hydroxy-succinimidylesters, hex- amethylenediisocyanat and N-( ⁇ -maleimidobutyryloxy)succinimide ester.
- a linking moiety 4 is present in the compound according to the inven- tion.
- j is selected from the group comprising aryl- ene(bisthiourea) and alkylene(bisthiourea).
- the linking molecule 1 ⁇ is phenylenebisthiourea.
- the compound comprises a biomolecule moiety, / ' . e. a peptide moiety, a linking moiety as well as an organo-silane moiety.
- the compound according to the invention may further comprises an adapter moiety interposed between the organo-silane moiety and the biomolecule moiety where said compound is represented by formula 5,
- the compound further comprises an adapter moiety inte ⁇ osed between the linking moiety and the biomolecule moiety where said compound is represented by formula 5 A.
- formula 5 A :
- Ri, R , and R 3 are each and independently alkoxy groups.
- BM represents the biomolecule moiety or a derivative thereof, n is an integer from 0 to 18, t represents the linking moiety and AM represents the adapter moiety.
- the adapter moiety "AM" is chosen from the group comprising -(CH 2 ) n and -[(CH ) 2 O] n wherein n is an integer from 0 to 18.
- biomolecule moiety is linked to the linking moiety or the to the adapter moiety via its N-terminal or its carboxy-terminal end.
- the peptides can be coupled to the silanes in a variety of ways.
- One method is to couple the peptides via a disulfide bond which could be cleavable, e.g. with the thiol side chain of Cys in proteins.
- Other methods include the maleimide-hinge technique, the succinimide technique or the like where the protein to be bound is. for example, an antibody.
- organic and aqueous solutions of gamma-aminopropyltriethoxysilane can be used in order to generate a number of reactive NH groups available for coupling to protein.
- the protein can be coupled to the silane by formation of Schiff s base linkages via glutaraldehyde.
- Another suited substance is trimethylchlorosilane
- Covalent immobilization of functional proteins on silica substrates can be performed using thiol-terminal silanes and heterobifunctional cross-linkers. Immobilization can further be performed directly via silanes carrying alkyl moieties with terminal carboxylic groups.
- the enzyme can also be covalently attached to phospholipid-bound silanes through the terminal carboxyl moiety on the sn-2 acyl chain of the lipid.
- peptide is an antibody or a functional part thereof.
- the antibody can be a monoclonal antibody, a humanized antibody or an scFv-fragment.
- the synthesis of the compound according to the invention is greatly facilitated if the biomolecule comprises a reactive group on a separate moiety which enables the binding to R* or alternatively to the organo-silane.
- the biomolecule comprises a reactive group on a separate moiety which enables the binding to R* or alternatively to the organo-silane.
- an adapter molecule may be characterised by formula 8,
- R_ 6 is selected from the group comprising cyanoethylphosphoramidites.
- Z is selected from the group comprising -NH , -SH and, n is an integer from 0 to 18.
- the invention also covers a process for the synthesis of a compound as disclosed above.
- an organo-silane is reacted with a biomolecule BM wherein, the organo-silane is represented by formula 7: formula 7:
- Rj, R 2 . and R 3 are each and independently an alkoxy group
- R 5 is selected from the group comprising -NH (-amino).
- -SH -sulfhydryl
- -NCO -cyanato
- -NHS ester hdroxysuc- cinimidylester. -acrylate
- n is an integer from 0 to 18.
- BM is reacted with an adapter molecule AM and subsequently reacted with the organo-silane.
- One reason for this is simply that e.g. if the biomolecule is a peptide such an adapter molecule may be coupled during on-line synthesis.
- the biomolecule may be initially reacted with a linking molecule and subsequently reacted with the organo-silane, or alternatively the organo-silane is reacted with the linking molecule and subsequently reacted with the biomolecule, wherein the linking molecule is a bifunctional reagent.
- a biomolecule is reacted with an adapter molecule resulting in reaction product A; reaction product A is reacted with a linking molecule resulting in reaction product B, and reaction product B is reacted with an organo-silane or alternatively,
- a biomolecule is reacted with an adapter molecule resulting in reaction product A; a linking molecule is reacted with an organo-silane resulting in reaction product C and reaction product A and C are reacted or alternatively,
- an adapter molecule is reacted with a linking molecule resulting in reaction product D, the reaction product D is reacted with the biomolecule resulting in reaction product B and reaction product B is reacted with an organo-silane or alternatively,
- an adapter molecule is reacted with a linking molecule resulting in reaction product D, the reaction product D is reacted with an organo-silane resulting in reaction product E and reaction product E is reacted with a biomolecule
- the biomolecule BM is reacted with a linking molecule j and subsequently reacted with the organo-silane or alternatively, the organo-silane is reacted with the linking molecule R and subsequently reacted with the biomolecule BM wherein, the linking molecule R is a bifunctional reagent.
- the process according to the invention does not require such a linking molecule R_ 4 the inventors find this to be advantageous.
- R ⁇ is selected from the group comprising cyanoethylphosphoramidites
- Z is selected from the group comprising -NH , -SH, -P0 . -COOH, -I and, n is an integer from 0 to 18.
- the linking molecule is a bifunctional reagent, i.e. a coupling reagent with two reactive groups.
- the linking molecule Rt is selected from the group comprising arylenediisothiocya- nate, alkylenediisothiocyanate, bis-N-hydroxy-succinimidylesters, hexamethylenediisocyanate and N-( ⁇ -maleimidobutyryloxy)succinimide ester. It is evident that these are preferred examples and one skilled in the art may find other possible bifunctional reagents which are equally within the scope of the invention.
- linking molecule R4 is 1 ,4-phenylene diisothiocyanate.
- the inventors have coupled the compound according to the invention to glass supports (see example X and Y) and performed solid-support nucleic acid synthesis reactions. This has drastic implications for the use of the compound according to the invention. Only to name a few of the advantages this incurs e.g. the background reduction will make it possible to perform solid-phase quantification experiments much more precisely, the bottom detection limit of analytes will drop, thus more precise results will be obtainable in various fields where the compound according to the invention finds applications.
- the compound according to the invention is preferentially used in solid-phase reactions here the compound may be bound to substances chosen from the group comprising nitrocellulose, nylon, controled-pore glass beads (CPG), polystyrene, activated dextran, modified polystyrene, styrene- acrylnitril-copolymers, polycarbonate, cellulose, polyamide and glass.
- CPG controled-pore glass beads
- a support is glass. This may be done simply by incubating a clean glass slide with the compound comprising the organo-silane moiety and the biomolecule moiety. Thus, supports may be obtained comprising the compound according to the invention.
- a support comprising a compound according to the invention exhibits a coating density of at least 1 pmol of biomolecule per mm", often 10 pmol of biomolecule per mm 2 up to 80 pmol of biomolecule per mm 2 and even higher. These high figures are not achievable when applying prior-art technology.
- the compound is used with glass although it may also be used in combination with any other solid-support.
- glass may be a glass slide, as used e.g. for microscopy, glass vessels or containers, glass fibers, glass beads or other -Si comprising glass entities.
- the compound according to the invention may be spotted onto, pipetted onto, sprayed onto or otherwise brought onto such a glass support.
- Possible methods are, application by means of a needle, capillary, dispenser and piezo pipette is preferable, e.g. an apparatus similar to the kind known for ink jet printers.
- the compound according to the invention may be used in various ways some of which shall be mentioned here.
- the compound is particularly suited for nucleic acid hybridization or synthesis reactions.
- the compound may be bound to a solid support such as glass.
- the compound represents one or more nucleic acid probes to which a target, i.e. the sample is bound.
- Such hybridisation experiments are disclosed in WO 95/00530.
- the compound according to the invention may be used to distinguish single base mismatches.
- U.S. Pat. 5,700,638 such experiments are described in Example 2.
- US Pat. 5,552.270 also describes such an approach.
- the compound according to the invention comprises an oligonucleotide of defined sequence.
- An array is generated comprising numerous different sequences each suited to test a defined sequence.
- the compound according to the invention may be used to analyse the expression of genes.
- the compound according to the invention may be used to map genomes of organisms.
- the compound according to the invention may comprise enzymatic functions as BM. In each case, this facilitates solid-support enzymatic reactions.
- the compound is used for nucleic acid synthesis reactions.
- the BM of the compound is preferentially a template dependent polymerase.
- At least one compound according to the invention is bound to a solid-support.
- a DNA polymerase may be selected from the group comprising Taq DNA polymerase, Tth DNA polymerase or Klentaq (Taq DNA polymerase (-exo5'-3'), Korolev et al., (1995) Proc. Natl. Acad. Sci. USA 92. 9246-9268.
- Taq DNA polymerase -exo5'-3'
- Korolev et al. (1995) Proc. Natl. Acad. Sci. USA 92. 9246-9268.
- the use of Taq DNA polymerase in the method of the present invention is especially preferred.
- a DNA polymerase which has a decreased discrimination against the four ddNTPs with respect to wild-type Taq DNA polymerase in the buffer or under the conditions used for thermal cycling is preferred. More preferably, a DNA polymerase Taq polymerase carrying a "Tabor-Richardson" mutation or a functional derivative thereof which also lacks 5'-3' exonuclease activity such as, for example, AmplitaqFSTM (Taq
- DNA polymerase (-exo5'-3')(F667Y), Tabor and Richardson (1995), loc. cit.), TaquenaseTM (Taq
- SequenaseTM (Taq DNA polymerase (-exo5'-3')(F667Y), Tabor and Richardson (1995), loc. cit.) as well as mixtures thereof or other DNA polymerases and mixtures thereof which are thermally stable can be used in the process of the present invention.
- Thermo SequenaseTM or any other DNA polymerase having a high ability to inco ⁇ erate ddNTPs in the method of the present invention is especially preferred.
- a DNA polymerase which has a decreased discrimination against labeled nucleotide may be used.
- the present invention i.e. the process also provides for the use of two or more polymerases in the process or additional enzymes such as amplification enhancing reagents such as thermostable pyrophosphatase or enzymes which enhance the processivity of the polymerase such as PCNA (proliferating cell nuclear antigen) homologues. Enzyme mixtures may be equally applied.
- the number of thermal cycles may range from about 1 to about 50 depending on the amount of template DNA and its purity. Generally, the inventors have found that very su ⁇ risingly extremely short cycles give good results. As the availability of the compound according to the invention is high in the process according to the invention the cycle period may be short, thus disadvantageous denaturing of proteins, e.g. the polymerase when in contact with glass occurs at a lower rate and the reaction may run efficiently without loss of function of enzyme.
- cycling consists of (i) a denaturing cycle, (ii) an annealing cycle and (iii) an extension cycle. Alternatively, only two cycles may be applied, (i) a denaturing cycle and (ii) an annealing and extension cycle.
- the denaturing cycle is performed at between 100°C and 85°C, more preferably at between 98°C and 90°C, most preferably at between 96°C and 92°C.
- the annealing cycle is performed at between 80°C and 45°C. more preferably at between 70°C and 50°C, most preferably at between 60°C and 55°C.
- the extension cycle is performed at between 80°C and 50°C. more preferably at between 75°C and 60°C, most preferably at between 73°C and 68°C.
- the denaturing cycle is performed for 3 minutes, more preferably for 30 seconds, most preferably for under 10 seconds.
- the annealing cycle is performed for 3 minutes, more preferably for 30 seconds, most preferably for under 10 seconds.
- the extension cycle is performed for 3 minutes, more preferably for 30 seconds, most preferably for under 10 seconds, however the extension time vary depending on the length of the template, in particular the extension time may be raised if the template length increases.
- Buffers components which can be used can include, but are not limited to, Tris-HCl at a pH of about 7.0 to 10 and concentration of about 2 to 60 mM, ammonium sulfate at a concentration of about 10-20 mM, preferably 15 mM, MgCb at a concentration of about 1 to 10 mM, and optionally, about 0.05 mM mercaptoethanol. about 0.28% Tween® 20 and/or about 0.02% Nonidet® 40.
- Nucleotide triphosphates are preferably deoxynucleotides and can be selected from, but are not limited to, dGTP, dATP, dTTP and dCTP.
- derivatives of deoxynucleotides which are defined as those deoxynucleotides which are capable of being inco ⁇ erated by a thermally stable DNA polymerase into nascent DNA molecules synthesized in the thermal cycling reaction, can also be used according to the invention.
- Such derivatives include, but are not limited to thionucleotides, 7-deaza-2'-dGTP, 7-deaza-2'-dATP as well as deoxyinosine triphosphate which may also be used as a replacement deoxynucleotide for dATP.
- dGTP, dTTP or dCTP deoxynucleotides and derivatives thereof are preferably used at a concentration of about 50 ⁇ M to about 4 mM.
- the nucleotides are mixes of all four and at 200 ⁇ M per nucleotide.
- one or more of the nucleotides inco ⁇ orated are labelled.
- single and differential labels may consist of the group comprising enzymes such as ⁇ - galactosidase. alkaline phosphatase and peroxidase, enzyme substrates, coenzymes. dyes, chro- mophores, fluorescent, chemiluminescent and bioluminescent labels such as FITC, Cy5, Cy5.5,
- the nucleic acid molecule to be amplified can be present in the form of total genomic DNA, which is preferably in an uncloned or unpurified form.
- the genomic DNA has a length greater than or equal to 2 kb.
- all forms of template may be used, e.g. purified nucleic acids, i.e. nucleic acids where one fraction may be enriched or not, one example being plasmid DNA the other purified genomic DNA.
- the process may be suited for use with complex mixtures of DNA such being purified but not substantially fractionated genomic DNA or non-complex mixtures such being purified and substantially fractionated DNA e.g. plasmid DNA.
- the nucleic acid molecule to be amplified can be present in the form of RNA.
- One polymerase or a mixture of two polymerases maybe utilized: a first DNA polymerase for example, Taq polymerase, and a second DNA polymerase with the capability to reverse transcribe RNA into DNA preferably Taq DNA polymerase (Jones et al., Nucl. Acids Res. 17: 8387-8388 (1989)) or Tth DNA polymerase (Myers et al., Biochemistry 30: 7666-7672 (1991)).
- the invention also covers a kit for use in molecular biology or chemistry comprising at least the compound according to the invention.
- the kit may also comprise other reagents or enzymes such as buffers, nucleotides or the like.
- the kit may be used for diagnostics.
- the kit may comprise a compound according to the invention or a compound according to the invention bound to a solid support, wherein the biomolecule moiety is represented by one or more oligonucleotides specific for particular e.g. genes or alleles.
- Example 1 (protein binding and detection):
- the activated protein solution was spotted directly without further purification using a GMS 417 Arrayer (Genetic MicroSystems) at 1 hit per dot (corresponds to approximately 0.5 nl applied to the glass surface in a spot with a diameter of 180 ⁇ m). After the spotting process the slides were washed twice with water and air-dried.
- GMS 417 Arrayer Genetic MicroSystems
- Example 2 (immobilization of protein molecules on untreated glass surfaces via indirect coupling to an NH 2 -silane moiety by EDC-mediated activation of COOH- groups)
- EDC is a popular carbodiimide that is widely used in reactions for conjugating biomolecules
- F sex factor encodes a single-stranded DNA binding protein (SSB) with extensive homology to Escherichia coli SSB. Proc. Natl Acad. Sci. U.S.A., 80, 5480-5484).
- SSB single-stranded DNA binding protein
- sulfo-NHS cf. Materials
- the hydroxyl of sulfo-NHS reacts with the EDC active-ester intermediate forming a sulfo-NHS ester that enhances the stability of the activated carboxylate.
- the resulting product is a stable amide linkage.
- Proteins are large biomolecules that contain a number of carboxyl (COOH) groups in their amino acid side chains (e.g. asp, glu) as well as on their carboxy-terminal end. Upon incubation with EDC or EDC/Sulfo-NHS one or more of these functional COOH-groups can be activated, ultimately forming a covalent linkage with the primary amine of APTS (cf. Materials) provided in the solution.
- COOH carboxyl
- Immobilization was carried out at one hit per dot followed by a double washing step for 3 seconds in HPLC- purified water after each spotting step.
- Each protein-silane-EDC solution used was spotted in rows of 10 as a control of spotting quality (Fig. 2). After the spotting process was complete, the slides were removed carefully from the spotting hood, transferred to a humid chamber and incubated over night at room temperature.
- fluorescence-labeled antibodies were diluted in lx TBST (10 mM Tris/150 mM sodium chloride/0,5 % Tween-20/pH 8.0 adjusted with HC1). Various dilutions of antibody were assayed for their performance in the solid phase immunoassay. Working dilutions of the labelled antibody usually were in the range of 1 :500 - 1 :1000.
- the assay was carried out by transferring the diluted antibody to the arrayed proteins on the glass surface and further incubation in a humid chamber for 60' at room temperature. Following the immunoassay the slide was rinsed briefly with HPLC-purified water and used for a pre-scan. For a washing step, the slide was transferred to a Falcon tube containing lxTBST with vigorous shaking on an Eppendorf Incubator.
- FIG. 3 An example of such an immunoassay is depicted in Fig. 3. Three rows of a BSA/EDC/APTS solution have been spotted on untreated glass slides each represented by ten identical replicates (BSA). The latter demonstrates the homogeneity of spot mo ⁇ hology and assay quality in the immunological detection reaction carried out thereafter. As a control, an identical array of an APTS/EDC coupling reaction containing no BSA has been spotted in parallel (Control). The immunoassay using labeled anti-BSA antibody demonstrates that the silane-coupled BSA is retained on the glass surface and can be detected by a sensitive biological binding assay. Evidently. no background binding to the untreated glass surface has been observed and unspecific binding to the APTS/EDC mixture alone is negligible.
- microscopy slides were immersed in a 1 :1 solution of 1- methanol/hydrochloric acid for at least 12 hours at room temperature. The slides were rinsed in HPLC-purified water extensively, dried under compressed air and used for spotting immediately.
- a 97% solution of APTS was purchased from SIGMA-Aldrich.
- a 5% working solution of was prepared by a dilution in HPLC-purified water. The solution can be stored at room temperature and should be stable at least one month.
- EDC l-ethyl-3-(3-dimethylaminopropyl)carbodiimide
- EDAC EDAC
- NHS N- Hydroxysulfosuccinimide
- EDC and sulfo-NHS were obtained from SIGMA-ALDRICH.
- a working solution of 100 mg/ml EDC was prepared by dissolving the according quantity of EDC powder in HPLC-purified water. Accordingly, a 100 mg/ml working solution of Sulfo-NHS was prepared in HPCL-purified water. Both solutions were freshly prepared prior to their use.
- Bovine serum albumin (BSA) was purchased form SIGMA-ALDRICH. BSA protein powder was dissolved in HPLC-purified water to obtain a 20 mg/ml concentration and stored at 4°C.
- Anti-bovine serum albumin antibody was purchased from SIGMA-ALDRICH. The antibodv was labeled with a commercially available Cy3 fluorescence dye from Amersham according to the manufacturer's protocol. The labelled antibody was stored at -20°C in aliquots of 100 ⁇ l..
- Fig. 1 shows the detection of a specific protein immobilized using the organo-silane derivatiza- tion protocol according to the invention.
- the figure shows the fluorescent image of the immunoassay specifically detecting immobilized BSA using a CY-3 labeled monoclonal anti-BSA antibody.
- the array contains 3 columns with 10 replicate spots each.
- the control spots contained no protein.
- Fig. 2 shows an schematic outline of the immobilization of protein molecules on untreated glass surfaces via indirect coupling to an NH 2 -silane moiety by EDC-mediated activation of COOH- groups according to example 2.
- Fig. 3 shows the results of an immunoassay for detection of immobilized proteins on the glass surface using fluorescence-labeled antibodies.
- the figure shows the fluorescent image of the immuno-assay specifically detecting immobilized BSA using a CY-3 labeled monoclonal antibody.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Structural Engineering (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne un composé comprenant un groupe fonctionnel biomolécule et un groupe fonctionnel silane organique, ainsi que le procédé de synthèse correspondant. L'invention concerne également un support contenant le groupe fonctionnel biomolécule et le groupe fonctionnel silane organique, dans lequel le groupe fonctionnel biomolécule est fixé au support via le groupe fonctionnel silane organique. L'invention concerne en outre une réaction de synthèse d'acide nucléique utilisant le groupe fonctionnel biomolécule et le groupe fonctionnel silane organique, ainsi que de nouvelles utilisations dudit composé. L'invention concerne enfin un kit contenant ce composé comprenant un groupe fonctionnel biomolécule et un groupe fonctionnel silane organique.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00993511A EP1252172A2 (fr) | 1999-12-21 | 2000-12-21 | Compose comprenant un groupe fonctionnel peptidique et un groupe fonctionnel silane organique |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99125484A EP1111068A1 (fr) | 1999-12-21 | 1999-12-21 | Composé ramifié pour l'utilisation dans des réactions d'analyse et de détection des acides nucléiques |
EP99125485 | 1999-12-21 | ||
EP99125485A EP1110967A1 (fr) | 1999-12-21 | 1999-12-21 | Composé comprenant un biomolecule et un organosilane |
EP99125484 | 1999-12-21 | ||
US21121700P | 2000-06-13 | 2000-06-13 | |
US21120900P | 2000-06-13 | 2000-06-13 | |
US211209P | 2000-06-13 | ||
US211217P | 2000-06-13 | ||
EP00993511A EP1252172A2 (fr) | 1999-12-21 | 2000-12-21 | Compose comprenant un groupe fonctionnel peptidique et un groupe fonctionnel silane organique |
PCT/EP2000/013099 WO2001046213A2 (fr) | 1999-12-21 | 2000-12-21 | Compose comprenant un groupe fonctionnel peptidique et un groupe fonctionnel silane organique |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1252172A2 true EP1252172A2 (fr) | 2002-10-30 |
Family
ID=56290094
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00991249A Withdrawn EP1250344A2 (fr) | 1999-12-21 | 2000-12-21 | Compose comprenant un groupe fonctionnel d'acide nucleique et un groupe fonctionnel silane organique |
EP00985230A Withdrawn EP1244812A1 (fr) | 1999-12-21 | 2000-12-21 | Compose ramifie s'utilisant dans des reactions de detection et d'analyse d'acide nucleique |
EP00993511A Withdrawn EP1252172A2 (fr) | 1999-12-21 | 2000-12-21 | Compose comprenant un groupe fonctionnel peptidique et un groupe fonctionnel silane organique |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00991249A Withdrawn EP1250344A2 (fr) | 1999-12-21 | 2000-12-21 | Compose comprenant un groupe fonctionnel d'acide nucleique et un groupe fonctionnel silane organique |
EP00985230A Withdrawn EP1244812A1 (fr) | 1999-12-21 | 2000-12-21 | Compose ramifie s'utilisant dans des reactions de detection et d'analyse d'acide nucleique |
Country Status (3)
Country | Link |
---|---|
EP (3) | EP1250344A2 (fr) |
AU (3) | AU2170901A (fr) |
WO (3) | WO2001046214A2 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1759210B1 (fr) * | 2001-07-13 | 2008-12-31 | Nanosphere, Inc. | Procede pour la preparation de substrats comportant des molecules immobilisees et substrats |
AU2003233595A1 (en) | 2002-05-20 | 2003-12-12 | Dow Corning Corporation | Peptide derivatives, and their use for the synthesis of silicon-based composite materials |
DE60335798D1 (de) | 2002-05-20 | 2011-03-03 | Danisco Us Inc | Synthese von anorganischen strukturen unter verwendung von templates und katalyse durch selbstangeordnete repeat-protein-polymere |
US7534621B2 (en) | 2003-02-07 | 2009-05-19 | Canon Kabuhsiki Kashia | Method of producing probe medium and method of immobilizing probe using probe medium |
US20050142094A1 (en) | 2003-03-12 | 2005-06-30 | Manoj Kumar | Use of repeat sequence protein polymers in personal care compositions |
US7297678B2 (en) | 2003-03-12 | 2007-11-20 | Genencor International, Inc. | Use of repeat sequence protein polymers in personal care compositions |
JP4629046B2 (ja) | 2003-05-14 | 2011-02-09 | ダニスコ・ユーエス・インコーポレーテッド | 反復配列タンパク質ポリマー活性剤結合体、方法および使用 |
US7456147B2 (en) | 2003-05-14 | 2008-11-25 | Dow Corning, Corporation | Controlled release of active agents utilizing repeat sequence protein polymers |
US20050208538A1 (en) | 2003-12-29 | 2005-09-22 | Nurith Kurn | Methods for analysis of nucleic acid methylation status and methods for fragmentation, labeling and immobilization of nucleic acids |
US7940746B2 (en) | 2004-08-24 | 2011-05-10 | Comcast Cable Holdings, Llc | Method and system for locating a voice over internet protocol (VoIP) device connected to a network |
WO2013059746A1 (fr) | 2011-10-19 | 2013-04-25 | Nugen Technologies, Inc. | Compositions et procédés pour l'amplification et le séquençage directionnels d'acide nucléique |
WO2013072408A1 (fr) * | 2011-11-15 | 2013-05-23 | Swetree Technologies Ab | Fibres cellulosiques à surface fonctionnalisée, procédé de fabrication associé et application associée |
WO2013112923A1 (fr) | 2012-01-26 | 2013-08-01 | Nugen Technologies, Inc. | Compositions et procédés pour l'enrichissement en séquence d'acide nucléique ciblée et la génération d'une banque à efficacité élevée |
WO2013191775A2 (fr) | 2012-06-18 | 2013-12-27 | Nugen Technologies, Inc. | Compositions et procédés pour la sélection négative de séquences d'acide nucléique indésirable |
US20150011396A1 (en) | 2012-07-09 | 2015-01-08 | Benjamin G. Schroeder | Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing |
EP2971130A4 (fr) | 2013-03-15 | 2016-10-05 | Nugen Technologies Inc | Séquençage séquentiel |
JP6525473B2 (ja) | 2013-11-13 | 2019-06-05 | ニューゲン テクノロジーズ, インコーポレイテッド | 複製物配列決定リードを同定するための組成物および方法 |
US9745614B2 (en) | 2014-02-28 | 2017-08-29 | Nugen Technologies, Inc. | Reduced representation bisulfite sequencing with diversity adaptors |
WO2016022833A1 (fr) | 2014-08-06 | 2016-02-11 | Nugen Technologies, Inc. | Mesures numériques à partir de séquençage ciblé |
US11099202B2 (en) | 2017-10-20 | 2021-08-24 | Tecan Genomics, Inc. | Reagent delivery system |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS608745B2 (ja) * | 1978-02-14 | 1985-03-05 | 三洋化成工業株式会社 | 免疫活性物質−つや消しガラス複合体,その製造法及び該複合体を含有してなる測定試薬 |
US4284553A (en) * | 1980-06-20 | 1981-08-18 | North Carolina State University At Raleigh | Reversible method for covalent immobilization of biochemicals |
IL78678A0 (en) * | 1986-05-04 | 1986-08-31 | Yeda Res & Dev | Substituted silica |
US5359100A (en) * | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
GB9104453D0 (en) * | 1991-03-02 | 1991-04-17 | Tepnel Medical Ltd | Improvements relating to enzymes |
US5290440A (en) * | 1992-06-23 | 1994-03-01 | Research Corporation Technologies, Inc. | High performance chiral selector |
US5641658A (en) * | 1994-08-03 | 1997-06-24 | Mosaic Technologies, Inc. | Method for performing amplification of nucleic acid with two primers bound to a single solid support |
FR2726286B1 (fr) * | 1994-10-28 | 1997-01-17 | Genset Sa | Procede d'amplification d'acides nucleiques en phase solide et trousse de reactifs utile pour la mise en oeuvre de ce procede |
AU5871196A (en) * | 1995-05-23 | 1996-12-24 | Hybridon, Inc. | Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced |
US5912332A (en) * | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
US5916750A (en) * | 1997-01-08 | 1999-06-29 | Biogenex Laboratories | Multifunctional linking reagents for synthesis of branched oligomers |
EP1017848B2 (fr) * | 1997-07-28 | 2012-02-22 | Gen-Probe Incorporated | Analyse de sequences nucleotidiques |
WO1999011820A1 (fr) * | 1997-09-02 | 1999-03-11 | Isis Pharmaceuticals, Inc. | Compositions et procedes d'identification et de quantification d'oligonucleotides a sequence de deletion dans des preparations d'oligonucleotides de synthese |
AU3463699A (en) * | 1998-04-03 | 1999-10-25 | Phylos, Inc. | Addressable protein arrays |
US6048695A (en) * | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
DE19825899A1 (de) * | 1998-06-10 | 1999-12-16 | Memorec Medical Molecular Rese | Vorrichtung zur parallelen Identifizierung und Quantifizierung von Polynukleinsäuren |
-
2000
- 2000-12-21 EP EP00991249A patent/EP1250344A2/fr not_active Withdrawn
- 2000-12-21 AU AU21709/01A patent/AU2170901A/en not_active Abandoned
- 2000-12-21 EP EP00985230A patent/EP1244812A1/fr not_active Withdrawn
- 2000-12-21 WO PCT/EP2000/013100 patent/WO2001046214A2/fr active Search and Examination
- 2000-12-21 AU AU28432/01A patent/AU2843201A/en not_active Abandoned
- 2000-12-21 EP EP00993511A patent/EP1252172A2/fr not_active Withdrawn
- 2000-12-21 WO PCT/EP2000/013098 patent/WO2001046464A1/fr not_active Application Discontinuation
- 2000-12-21 AU AU31631/01A patent/AU3163101A/en not_active Abandoned
- 2000-12-21 WO PCT/EP2000/013099 patent/WO2001046213A2/fr not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0146213A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001046214A3 (fr) | 2001-12-27 |
EP1244812A1 (fr) | 2002-10-02 |
AU2843201A (en) | 2001-07-03 |
WO2001046213A2 (fr) | 2001-06-28 |
WO2001046464A1 (fr) | 2001-06-28 |
AU3163101A (en) | 2001-07-03 |
WO2001046213A3 (fr) | 2002-05-10 |
EP1250344A2 (fr) | 2002-10-23 |
WO2001046214A2 (fr) | 2001-06-28 |
AU2170901A (en) | 2001-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001046213A2 (fr) | Compose comprenant un groupe fonctionnel peptidique et un groupe fonctionnel silane organique | |
US6858713B1 (en) | Chemically modified biological molecules and methods for coupling biological molecules to solid support | |
US7658946B2 (en) | Solid supports functionalized with phosphorus-containing dendrimers, process for preparing them and uses thereof | |
WO2001059161A2 (fr) | Dosages d'analytes utilisant des reseaux universels | |
US7485469B2 (en) | Method for attachment of silylated molecules to glass surfaces | |
KR20010020283A (ko) | 분석 실행 장치, 그 장치의 제조 방법 및 그 장치의 제조에 멤브레인을 사용하는 방법 | |
US5702893A (en) | Hydrophobic nucleic acid probe | |
US20170101665A1 (en) | Nucleic Acid Amplification With Integrated Multiplex Detection | |
CN101848939A (zh) | G蛋白-寡核苷酸偶联物 | |
US20080254999A1 (en) | Linear nucleic acid and sequence therefor | |
JP2004506922A (ja) | バイオチップマイクロアレイを構築するための固体支持体の表面活性化を得る方法 | |
US6855539B2 (en) | Device for performing an assay, a method for manufacturing said device, and use of a membrane in the manufacture of said device | |
US20080146459A1 (en) | Protein Array and Process for Producing the Same | |
US7049073B2 (en) | Double stranded nucleic acid biochips | |
EP1127166A1 (fr) | Procede et systeme d'analyse a reseau amplifie | |
US20040259094A1 (en) | Method of attachment of a biomolecule to a solid surface | |
AU2002327961A1 (en) | Method of attachment of a biomolecule to a solid surface | |
Liao et al. | Novel probes for protein chip applications | |
EP1110967A1 (fr) | Composé comprenant un biomolecule et un organosilane | |
EP1256805B1 (fr) | Puce de matériaux biologiques | |
JP2002365291A (ja) | 反応性核酸断片及び相補性dna断片検出用具の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020718 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20040308 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040720 |